Therapeutic implication: Ferroptosis inducers (erastin, sorafenib, and artesunate) inhibit RCC progression (227, 233); ferroptosis-related genes (GPX4 and ACSL4) serve as prognostic biomarkers (233), supporting precision therapy development. Here, ACSL4 is linked to renal cell carcinoma.